BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

451 related articles for article (PubMed ID: 15958626)

  • 1. Gene expression profiling of progressive papillary noninvasive carcinomas of the urinary bladder.
    Wild PJ; Herr A; Wissmann C; Stoehr R; Rosenthal A; Zaak D; Simon R; Knuechel R; Pilarsky C; Hartmann A
    Clin Cancer Res; 2005 Jun; 11(12):4415-29. PubMed ID: 15958626
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An immunohistochemical and prognostic evaluation of cathepsin D expression in 105 bladder carcinomas.
    Dickinson AJ; Fox SB; Newcomb PV; Persad RA; Sibley GN; Harris AL
    J Urol; 1995 Jul; 154(1):237-41. PubMed ID: 7776437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Protein expression and gene copy number analysis of topoisomerase 2alpha, HER2 and P53 in minimally invasive urothelial carcinoma of the urinary bladder--a multitissue array study with prognostic implications.
    Krüger S; Lange I; Kausch I; Feller AC
    Anticancer Res; 2005; 25(1A):263-71. PubMed ID: 15816547
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defining molecular profiles of poor outcome in patients with invasive bladder cancer using oligonucleotide microarrays.
    Sanchez-Carbayo M; Socci ND; Lozano J; Saint F; Cordon-Cardo C
    J Clin Oncol; 2006 Feb; 24(5):778-89. PubMed ID: 16432078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased expression of galectin-3 predicts tumour recurrence in pTa bladder cancer.
    Kramer MW; Kuczyk MA; Hennenlotter J; Serth J; Schilling D; Stenzl A; Merseburger AS
    Oncol Rep; 2008 Dec; 20(6):1403-8. PubMed ID: 19020721
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bladder cancer outcome and subtype classification by gene expression.
    Blaveri E; Simko JP; Korkola JE; Brewer JL; Baehner F; Mehta K; Devries S; Koppie T; Pejavar S; Carroll P; Waldman FM
    Clin Cancer Res; 2005 Jun; 11(11):4044-55. PubMed ID: 15930339
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A molecular signature in superficial bladder carcinoma predicts clinical outcome.
    Dyrskjøt L; Zieger K; Kruhøffer M; Thykjaer T; Jensen JL; Primdahl H; Aziz N; Marcussen N; Møller K; Orntoft TF
    Clin Cancer Res; 2005 Jun; 11(11):4029-36. PubMed ID: 15930337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Motility-related protein 1 (MRP-1/CD9) expression in urothelial bladder carcinoma and its relation to tumor recurrence and progression.
    Mhawech P; Herrmann F; Coassin M; Guillou L; Iselin CE
    Cancer; 2003 Oct; 98(8):1649-57. PubMed ID: 14534881
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-cadherin as a novel prognostic marker of progression in superficial urothelial tumors.
    Lascombe I; Clairotte A; Fauconnet S; Bernardini S; Wallerand H; Kantelip B; Bittard H
    Clin Cancer Res; 2006 May; 12(9):2780-7. PubMed ID: 16675571
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of differentially expressed genes in human bladder cancer through genome-wide gene expression profiling.
    Kawakami K; Enokida H; Tachiwada T; Gotanda T; Tsuneyoshi K; Kubo H; Nishiyama K; Takiguchi M; Nakagawa M; Seki N
    Oncol Rep; 2006 Sep; 16(3):521-31. PubMed ID: 16865252
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular profiling of laser-microdissected matched tumor and normal breast tissue identifies karyopherin alpha2 as a potential novel prognostic marker in breast cancer.
    Dahl E; Kristiansen G; Gottlob K; Klaman I; Ebner E; Hinzmann B; Hermann K; Pilarsky C; Dürst M; Klinkhammer-Schalke M; Blaszyk H; Knuechel R; Hartmann A; Rosenthal A; Wild PJ
    Clin Cancer Res; 2006 Jul; 12(13):3950-60. PubMed ID: 16818692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of nm23-H1 in the progression of transitional cell bladder cancer.
    Chow NH; Liu HS; Chan SH
    Clin Cancer Res; 2000 Sep; 6(9):3595-9. PubMed ID: 10999750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FGFR3 mutations and a normal CK20 staining pattern define low-grade noninvasive urothelial bladder tumours.
    van Oers JM; Wild PJ; Burger M; Denzinger S; Stoehr R; Rosskopf E; Hofstaedter F; Steyerberg EW; Klinkhammer-Schalke M; Zwarthoff EC; van der Kwast TH; Hartmann A
    Eur Urol; 2007 Sep; 52(3):760-8. PubMed ID: 17240035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cytokeratin expression patterns in low-grade papillary urothelial neoplasms of the urinary bladder.
    Ramos D; Navarro S; Villamón R; Gil-Salom M; Llombart-Bosch A
    Cancer; 2003 Apr; 97(8):1876-83. PubMed ID: 12673713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identifying distinct classes of bladder carcinoma using microarrays.
    Dyrskjøt L; Thykjaer T; Kruhøffer M; Jensen JL; Marcussen N; Hamilton-Dutoit S; Wolf H; Orntoft TF
    Nat Genet; 2003 Jan; 33(1):90-6. PubMed ID: 12469123
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene signatures for the prediction of response to Bacillus Calmette-Guerin immunotherapy in primary pT1 bladder cancers.
    Kim YJ; Ha YS; Kim SK; Yoon HY; Lym MS; Kim MJ; Moon SK; Choi YH; Kim WJ
    Clin Cancer Res; 2010 Apr; 16(7):2131-7. PubMed ID: 20233890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bladder cancer stage and outcome by array-based comparative genomic hybridization.
    Blaveri E; Brewer JL; Roydasgupta R; Fridlyand J; DeVries S; Koppie T; Pejavar S; Mehta K; Carroll P; Simko JP; Waldman FM
    Clin Cancer Res; 2005 Oct; 11(19 Pt 1):7012-22. PubMed ID: 16203795
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression-specific genes identified by expression profiling of matched ductal carcinomas in situ and invasive breast tumors, combining laser capture microdissection and oligonucleotide microarray analysis.
    Schuetz CS; Bonin M; Clare SE; Nieselt K; Sotlar K; Walter M; Fehm T; Solomayer E; Riess O; Wallwiener D; Kurek R; Neubauer HJ
    Cancer Res; 2006 May; 66(10):5278-86. PubMed ID: 16707453
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.